| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Alpha-2A adrenergic receptor |
|---|
| Ligand | BDBM50312770 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | ChEMBL_615840 (CHEMBL1101950) |
|---|
| Ki | >10000±n/a nM |
|---|
| Citation |  Yu, M; Lizarzaburu, M; Beckmann, H; Connors, R; Dai, K; Haller, K; Li, C; Liang, L; Lindstrom, M; Ma, J; Motani, A; Wanska, M; Zhang, A; Li, L; Medina, JC Identification of piperazine-bisamide GHSR antagonists for the treatment of obesity. Bioorg Med Chem Lett20:1758-62 (2010) [PubMed] Article |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Alpha-2A adrenergic receptor |
|---|
| Name: | Alpha-2A adrenergic receptor |
|---|
| Synonyms: | ADA2A_HUMAN | ADRA2A | ADRA2R | ADRAR | Adrenergic alpha2A | Adrenergic receptor alpha | Alpha-2 adrenergic receptor subtype C10 | Alpha-2A adrenoceptor | Alpha-2A adrenoreceptor | Alpha-2AAR | alpha-2A adrenergic receptor [Homo sapiens] |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 48979.91 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | P08913 |
|---|
| Residue: | 465 |
|---|
| Sequence: | MFRQEQPLAEGSFAPMGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLML
LTVFGNVLVIIAVFTSRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAW
CEIYLALDVLFCTSSIVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVIS
FPPLISIEKKGGGGGPQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKR
RTRVPPSRRGPDAVAAPPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGP
RDTDALDLEESSSSDHAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTP
AAGPGEERVGAAKASRWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPR
TLFKFFFWFGYCNSSLNPVIYTIFNHDFRRAFKKILCRGDRKRIV
|
|
|
|---|
| BDBM50312770 |
|---|
| n/a |
|---|
| Name | BDBM50312770 |
|---|
| Synonyms: | (4-(1H-indole-6-carbonyl)piperazin-1-yl)(biphenyl-4-yl)methanone | CHEMBL1076586 |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C26H23N3O2 |
|---|
| Mol. Mass. | 409.4797 |
|---|
| SMILES | O=C(N1CCN(CC1)C(=O)c1ccc2cc[nH]c2c1)c1ccc(cc1)-c1ccccc1 |
|---|
| Structure | 
|
|---|
Search and Browse
